SCHEMBL26633751

SCHEMBL26633751

COc1ccc(CNC(=O)NC2CC3(C2)CN(S(=O)(=O)c2ccccc2Cl)C3)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ ALDH1A1 P00352 4/20 0.48
▸ TSHR P16473 1/20 0.48
▸ MAPK1 P28482 1/20 0.47
▸ MCHR1 Q99705 1/20 0.46
▸ HRH3 Q9Y5N1 1/20 0.46
▸ POLB P06746 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ PKM P14618 4/20 0.44
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ FAAH O00519 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30306676 0.89 EPHX1 (0.49) ALDH1A1POLBMAPTPKMKMT2A
SCHEMBL26764345 0.89 EPHX1 (0.49) ALDH1A1POLBMAPTPKMKMT2A
SCHEMBL24011378 0.88 SMN1; SMN2 (0.58) SMN1; SMN2RAB9ANPC1ALDH1A1TSHR
SCHEMBL30306649 0.85 MAPT (0.49) SMN1; SMN2RAB9ANPC1ALDH1A1TSHR
SCHEMBL26764206 0.85 MAPT (0.49) SMN1; SMN2RAB9ANPC1ALDH1A1TSHR
SCHEMBL26633905 0.85 L3MBTL1 (0.49) SMN1; SMN2RAB9ANPC1ALDH1A1TSHR
SCHEMBL26633890 0.84 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ANPC1ALDH1A1TSHR
SCHEMBL30306671 0.80 NPC1 (0.50) SMN1; SMN2RAB9ANPC1ALDH1A1MCHR1
SCHEMBL26764086 0.80 NPC1 (0.50) SMN1; SMN2RAB9ANPC1ALDH1A1MCHR1
SCHEMBL26764221 0.79 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115843295-B NAMPT modulators 赛特凯恩蒂克公司 2025-04-15 — — CN disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
CN-115843295-A NAMPT modulators 赛特凯恩蒂克公司 2023-03-24 — — CN disclosed
EP-4146640-A2 NAMPT MODULATORS Cytokinetics, Inc. (US) 2023-03-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT SMN1; SMN2 610/4885RAB9A 814/4885NPC1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback